Previous 10 | Next 10 |
Mental health is on the decline all over the world. In fact, as reported by Sky News, a report authored by the Lancet-World Psychiatric Association Commission estimates that, “around 5 per cent of the adult population around the world in any year is living with depression. In high-in...
Numinus offers a lower risk exposure to the psychedelics space in comparison to stocks focused on drug discovery and development. Capital flows into the sector have not yet recognized the importance of the therapeutic delivery model. Numinus has a healthy cash balance, a solid ind...
As more research has been demonstrating, psilocybin may be one of the best new treatments for not only treatment-resistant depression , but also Alzheimer’s, post-traumatic stress disorder, autism, alcoholism, smoking, and drug addiction, anxiety, obsessive-compul...
On December 16, 2021, researchers at Dell Medical School at The University of Texas at Austin launched the Center for Psychedelic Research and Therapy . The Texas center joins other similar centers in the U.S. in California (established in...
Gainers: Alnylam Pharmaceuticals (NASDAQ:ALNY) +12%. ImmunityBio (NASDAQ:IBRX) +6%. Ortho Clinical Diagnostics Holdings (NASDAQ:OCDX) +5%. Qorvo (NASDAQ:QRVO) +5%. Vanda Pharmaceuticals (NASDAQ:VNDA) +4%. Losers: COMPASS Pathways P(NASDAQ:CMPS) +-5%. GreenSky (NASD...
Leading psychedelics advocacy groups are tasked with goals of demonstrating and influencing the way that the psychedelics business operates. They create conferences, organize wellness seminars, provide teaching and training courses as a way of not only introducing psychedeli...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 – After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of approval from Health Canada for medical purposes....
The year 2021 has not been kind to the psychedelics industry. The stock performances of the 60 publicly traded psychedelics companies on the Psychedelic Stock Index have been trending steadily downward since February 22, 2021, to their lowest point since the index began ...
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and Sermo, a global leader in physician insights, today announced findings from a survey...
The rush to business maturity for the psychedelics industry has led to inevitable comparisons to the growth and development of the cannabis industry. Both have captured the interest of angel investors channeling millions of dollars into them. There are currently 60 publicly tr...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...